Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.99B

Market cap31.99B

Price-Earnings ratio

23.18

Price-Earnings ratio23.18

Dividend yield

—

Dividend yield—

Average volume

1.38M

Average volume1.38M

High today

—

High today—

Low today

—

Low today—

Open price

$215.49

Open price$215.49

Volume

0.00

Volume0.00

52 Week high

$219.72

52 Week high$219.72

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $217.00. The company's market cap stands at 31.99B, with a P/E ratio of 23.18.

Biogen(BIIB) stock opened on 2026-06-30 at $215.49. The price climbed to — and dipped to —.

The Biogen(BIIB)'s current trading volume is 0, compared to an average daily volume of 1.38M.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $219.72 at its peak.

BIIB News

Benzinga 21h

Biogen: Key Takeaways From Needham’s Meeting With Top Management

Spinraza HD uptake has been “quite positive,” with demand matching Spinraza’s launch levels, driven by both new and returning patients, Fadia wrote. She also ci...

TipRanks 1d

Biogen price target raised to $256 from $255 at Needham

Needham analyst Ami Fadia raised the firm’s price target on Biogen (BIIB) to $256 from $255 and keeps a Buy rating on the shares. The firm is incrementally more...

Simply Wall St 2d

Biogen Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond dec...

Analyst ratings

58%

of 38 ratings

Buy

57.9%

Hold

36.8%

Sell

5.3%

More BIIB News

Simply Wall St 4d

Biogen Is Betting Its Next Phase Of Growth On Four New Drugs

Biogen (NasdaqGS:BIIB) is shifting its focus from older multiple sclerosis and Spinraza products to newer drugs in Alzheimer's, Friedreich’s ataxia, ALS, and de...

Nasdaq 4d

Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?

Biogen BIIB is in the midst of a major portfolio transition. The company is seeing declining sales of its key multiple sclerosis (“MS”) drugs like Tecfidera and...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.